Entrega estimada en Estados Unidos, el Martes 7 de Enero de 2025
Información del producto
Nombre:
Irinotecan Hydrochloride Trihydrate
Producto controlado
Sinónimos:
- [1,4'-Bipiperidine]-1'-carboxylic acid (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester monohydrochloride trihydrate
- Irinotecan hydrochloride hydrate
- (+)-7-Ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin, monohydrochloride, trihydrate
- (+)-7-Ethyl-10-hydroxycamptothecine 10-(1,4'-bipiperidine)-1'-carboxylate, monohydrochloride, trihydrate
- (1,4'-Bipiperidine)-1'-Carboxylicacid,4,11-Diethyl-3,4,12,14-Tetrahydro-4-Hyd Monohydrochloride, Trihydrate
- (1,4'-Bipiperidine)-1'-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinolin-9-yl ester, monohydrochloride, trihydrate, (S)-
- (19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl [1,4'-bipiperidine]-1'-carboxylate trihydrate hydrochloride
- (S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl [1,4'-bipiperidine]-1'-carboxylate hydrochloride trihydrate
- (S)-[1,4'-Bipiperidine]-1'-Carboxylic Acid 4,11-Diethyl-3,4,12,14-Tetrahydro-4-Hydroxy-3,14-Dioxo-1H-Pyrano
- (S)-[1,4'-Bipiperidine]-1'-carboxylic acid 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester hydrochloride trihydrate
- Ver más sinónimos
- 1H-Pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline, [1,4′-bipiperidine]-1′-carboxylic acid deriv.
- Camptosar
- Irinotecan HCl trihydrate
- Irinotecan Monohydrochloride Trihydrate
- Irinotecanhydrochloridetrihydrate(Cpt-11)
- Onivyde
- Onivyde pegylated liposomal
- Roxy-3,14-Dioxo-1H-Pyrano(3',4',6,7)Indolizino(1,2-B)Quinolin-9-Ylester,Mono
- Trihydrate,(S)-Hydrochlorid Trihydrate
- [1,4'-Bipiperidine]-1'-Carboxylic Acid (S)-4,11-Diethyl-3,4,12,14-Tetrahydro-4-Hydroxy-3,14-Dioxo-1H-Pyrano
- [1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester, hydrochloride, hydrate (1:1:3)
- [1,4′-Bipiperidine]-1′-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester, hydrochloride, hydrate (1:1:3)
- [1,4′-Bipiperidine]-1′-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride, trihydrate
- [1,4′-Bipiperidine]-1′-carboxylic acid, 4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-9-yl ester, monohydrochloride, trihydrate, (S)-
- [3',4',6,7]Indolizino[1,2-B]Quinolin-9-Yl Ester, Hcl Trihydrate
- [3',4':6,7]Indolizino[1,2-B]Quinolin-9-Yl Ester Hydrochloride Trihydrate
Aviso:
Nuestros productos están destinados únicamente para uso en laboratorio. Para cualquier otro uso, por favor contáctenos.
Marca:
Mikromol
Almacenamiento de larga duración:
Notas:
Propiedades químicas
Peso molecular:
677.18
Fórmula:
C33H38N4O6·ClHH2O
Color/Forma:
Neat
InChI:
, /h8-9,16-17,20,41H,3-7,10-15,18-19H2,1-2H3, , 1H, , InChI=1S/C33H38N4O6.ClH.3H2O/c1-3-22-23-16-21(43-32(40)36-14-10-20(11-15-36)35-12-6-5-7-13-35)8-9-27(23)34-29-24(22)18-37-28(29)17-26-25(30(37)38)19-42-31(39)33(26,41)4-2, 3*1H2/t33-, , , , /m0..../s1
SMILES:
CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC.Cl.O.O.O
MDL:
Punto de fusión:
Punto de ebullición:
Punto de inflamabilidad:
Densidad:
Concentración:
EINECS:
Merck:
Código HS:
Consulta técnica sobre: 86-MM1157.00 Irinotecan Hydrochloride Trihydrate
Use el carrito para solicitar presupuestos o pedidos
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.